|
PHF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.78890000380028E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.6317000000331E-06 |
| Normal-vs-Stage2 |
4.982700E-04 |
| Normal-vs-Stage3 |
1.47680000450734E-08 |
| Normal-vs-Stage4 |
1.49639999946771E-07 |
| Stage1-vs-Stage2 |
8.485000E-01 |
| Stage1-vs-Stage3 |
3.506200E-02 |
| Stage1-vs-Stage4 |
8.297700E-02 |
| Stage2-vs-Stage3 |
2.280400E-01 |
| Stage2-vs-Stage4 |
2.444400E-01 |
| Stage3-vs-Stage4 |
9.121600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.40500000522792E-08 |
| Normal-vs-AfricanAmerican |
3.538200E-02 |
| Normal-vs-Asian |
8.980300E-04 |
| Caucasian-vs-AfricanAmerican |
1.537230E-01 |
| Caucasian-vs-Asian |
2.565000E-01 |
| AfricanAmerican-vs-Asian |
6.302600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.25549999999242E-06 |
| Normal-vs-Female |
8.44749999950878E-08 |
| Male-vs-Female |
8.237200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.31189999999604E-05 |
| Normal-vs-Age(41-60Yrs) |
8.79609999948627E-07 |
| Normal-vs-Age(61-80Yrs) |
3.24399995754732E-09 |
| Normal-vs-Age(81-100Yrs) |
7.795500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.210200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.352200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.471570E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.679960E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.776800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.045600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.978900E-04 |
| Classical-VS-Follicular |
2.213600E-01 |
| Classical-VS-Other |
8.013800E-01 |
| Classical-VS-Normal |
4.97139999999785E-06 |
| Tall-VS-Follicular |
2.760000E-02 |
| Tall-VS-Other |
5.228300E-02 |
| Tall-VS-Normal |
4.45159997752853E-09 |
| Follicular-VS-Other |
5.523200E-01 |
| Follicular-VS-Normal |
1.86654999999591E-05 |
| Other-VS-Normal |
1.362160E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.12089999959997E-07 |
| Normal-vs-N1 |
4.10710000000591E-05 |
| N0-vs-N1 |
9.514800E-01 |
|
|
